Pfizer-Biontech’s coronavirus vaccine offers more protection than earlier thought with effectiveness in preventing symptomatic disease reaching 97 per cent, according to real-world evidence published Thursday by pharma companies.
Using data from January 17 to March 6 from Israel’s national vaccination campaign, Pfizer-Biontech found that prevention against asymptomatic disease also reached 94 per cent.
An earlier real-world study had shown effectiveness at preventing symptomatic disease at 94 per cent and asymptomatic illness at 92 per cent. (AFP)
